The guidance document provides recommendations as to whether—and when—comparative clinical immunogenicity studies will be needed to support an application to the FDA for insulin products under the biosimilar approval pathway.
Vizient said this week it endorses the FDA’s draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.
The guidance document provides recommendations as to whether—and when—comparative clinical immunogenicity studies will be needed to support an application to the FDA for insulin products under the biosimilar approval pathway.
In March, insulins will be regulated as biologics, and as such, developers will be able to seek licensure for subsequent-entry insulins under the biosimilar approval pathway after that time, whereas they are currently treated as follow-ons.
In a statement, Vizient said it believes FDA’s the guidance will support a more effective and efficient approval process by streamlining clinical data requirements.
“Vizient fully supports scientifically justified opportunities to improve approval processes for biosimilars and interchangeable biologics, including insulins,” Steven Lucio, Vizient’s vice president, pharmacy solutions, said in a statement.
“The approval of more insulin biosimilars will enable patients with diabetes to have much needed access to more affordable treatment options,” he added; the change will create more competion and lower healthcare spending.
In its comment on the draft, Vizient wrote that the FDA's approach is justified "given the strength of analytical characterization data, the less complex structure of insulin, and the absence of a clinical impact of immunogenicity with insulin use."
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.